Compare · GNLX vs NVS
GNLX vs NVS
Side-by-side comparison of Genelux Corporation (GNLX) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GNLX and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $293.40B, about 2279.8x GNLX ($128.7M).
- Over the past year, GNLX is down 13.2% and NVS is up 34.6% - NVS leads by 47.8 points.
- GNLX has been more active in the news (4 items in the past 4 weeks vs 1 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 6 for GNLX).
- Company
- Genelux Corporation
- Novartis AG
- Price
- $2.87+1.41%
- $153.72+0.64%
- Market cap
- $128.7M
- $293.40B
- 1M return
- -5.44%
- +1.89%
- 1Y return
- -13.16%
- +34.60%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 4
- 1
- Recent ratings
- 6
- 25
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest GNLX
- Attovia Therapeutics Appoints John W. Smither to Board of Directors
- Director Smither John W sold $34,898 worth of shares (12,000 units at $2.91), decreasing direct ownership by 12% to 91,403 units (SEC Form 4)
- Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
- SEC Form 8-K filed by Genelux Corporation
- President and CEO Zindrick Thomas was granted 730,601 shares, increasing direct ownership by 137% to 1,263,913 units (SEC Form 4)
- General Counsel Groen Eric was granted 233,957 shares (SEC Form 4)
- Director Thomas John was granted 28,409 shares, increasing direct ownership by 6% to 501,193 units (SEC Form 4)
- Chief Financial Officer Pulisic Matthew was granted 278,906 shares (SEC Form 4)
- Director Tyree James L was granted 28,409 shares, increasing direct ownership by 42% to 96,483 units (SEC Form 4)
- Chief Technical Officer Cappello Joseph was granted 174,841 shares, increasing direct ownership by 113% to 329,390 units (SEC Form 4)
Latest NVS
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG